AVTX 10-Q: SEC filing
Avalo Therapeutics
Filed with the SEC on · accession 0001534120-26-000057
AVTX filed a 10-Q (quarterly report) with the SEC on Nov 5, 2026. The quarterly report: unaudited results for the quarter plus management’s comments.
Summary of the filing
Avalo Therapeutics filed its quarterly report on Form 10-Q for the period ended September 30, 2026, reporting financial results and subsequent events including preferred stock conversions.
Key details
✦ Ask GOAX AI about this filing — what it means for AVTX, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for AVTX?
Click hereFrequently asked questions
What did AVTX file with the SEC on Nov 5, 2026?
AVTX filed a 10-Q (SEC filing). Avalo Therapeutics filed its quarterly report on Form 10-Q for the period ended September 30, 2026, reporting financial results and subsequent events including preferred stock conversions.
How do I read a 10-Q?
The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.
Other AVTX SEC filings
- 10-Q · SEC filingAug 6, 2026
- 8-K · Guidance cutAug 6, 2026
- 424B3 · Secondary offeringJul 28, 2026
- S-3 · Shelf registrationJul 17, 2026
- 8-K · Board changeJun 23, 2026
- 8-K · SEC filingJun 16, 2026
- 8-K · SEC filingJun 12, 2026
- 8-K · SEC filingJun 8, 2026
- 144 · Insider sale plannedJun 2, 2026
- 8-K · SEC filingMay 13, 2026
Get alerts when AVTX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days